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 Patients with elevated liver fat and poor metabolic control
have impaired cardiac and autonomic function.
 Liver fat, metabolic dysfunction, inflammation and fibrosis
staging correlate with cardiac and autonomic dysfunction.
 Elevated alcohol intake enhanced the impact of liver fat on
diastolic autonomic dysfunction.David Houghton, Paweł Zalewski, Kate
Hallsworth, ..., Quentin M. Anstee, Julia L.
Newton, Michael I. Trenell
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Lay summary
Increased levels of fat in the liver impair
the ability of the cardiovascular system to
work properly. The amount of fat in the
liver, metabolic control, inflammation
and alcohol are all linked to the degree
that the cardiovascular system is affected.Genetic and Metabolic Diseaseshe Study of the Liver. This is an open access article under
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Background & Aims: Cardiovascular disease is the principle
cause of death in patients with elevated liver fat unrelated to
alcohol consumption, more so than liver-related morbidity
and mortality. The aim of this study was to evaluate the rela-
tionship between liver fat and cardiac and autonomic function,
as well as to assess how impairment in cardiac and autonomic
function is influenced by metabolic risk factors.
Methods: Cardiovascular and autonomic function were
assessed in 96 sedentary individuals: i) non-alcoholic fatty liver
disease (NAFLD) (n = 46, hepatic steatosis >5% by magnetic res-
onance spectroscopy), ii) Hepatic steatosis and alcohol (dual
aetiology fatty liver disease [DAFLD]) (n = 16, hepatic steatosis
>5%, consuming >20 g/day of alcohol) and iii) CONTROL
(n = 34, no cardiac, liver or metabolic disorders, <20 g/day of
alcohol).
Results: Patients with NAFLD and DAFLD had significantly
impaired cardiac and autonomic function when compared with
controls. Diastolic variability and systolic variability (LF/HF-sBP
[n/1]; 2.3 (1.7) and 2.3 (1.5) vs. 3.4 (1.5), p <0.01) were impaired
in patients with NAFLD and DAFLD when compared to controls,
with DAFLD individuals showing a decrease in diastolic variabil-
ity relative to NAFLD patients. Hepatic steatosis and fasting glu-
cose were negatively correlated with stroke volume index.
Fibrosis stage was significantly negatively associated with mean
blood pressure (r = 0.47, p = 0.02), diastolic variability
(r = 0.58, p ≤0.01) and systolic variability (r = 0.42, p = 0.04).
Hepatic steatosis was independently associated with cardiac
function (p ≤0.01); TNF-a (p ≤0.05) and CK-18 (p ≤0.05) were
independently associated with autonomic function.
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Conclusion: Cardiac and autonomic impairments appear to be
dependent on level of liver fat, metabolic dysfunction, inflam-
mation and fibrosis staging, and to a lesser extent alcohol
intake. Interventions should be sought to moderate the excess
cardiovascular risk in patients with NAFLD or DAFLD.
Lay summary: Increased levels of fat in the liver impair the abil-
ity of the cardiovascular system to work properly. The amount
of fat in the liver, metabolic control, inflammation and alcohol
are all linked to the degree that the cardiovascular system is
affected.
 2019 The Authors. Published by Elsevier B.V. on behalf of
European Association for the Study of the Liver. This is an open
access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
Introduction
Current clinical care in chronic liver disease divides fatty liver
disease into non-alcoholic fatty liver disease (NAFLD) or alco-
holic fatty liver disease (ALD), predominantly based on alcohol
intake.1 In line with the increase in obesity NAFLD has become
the leading cause of liver disease in developed countries,2,3 clo-
sely followed by ALD, which together account for the 2 most
common liver diseases worldwide.4
NAFLD and ALD encompass a spectrum of clinical features,
with similar pathophysiology and histological features ranging
from steatosis, steatohepatitis, fibrosis and cirrhosis, with more
advanced forms of the disease causing considerable liver mor-
tality and morbidity.5 The clinical and economic burden of
NAFLD and ALD is not only dependent on liver-related mortal-
ity, but is also due to extrahepatic diseases (type 2 diabetes, kid-
ney disease) and increased risk of cardiovascular disease
(CVD).6,7
CVD rather than liver-related death, is a more common out-
come in patients with NAFLD,8 however, liver-related deaths are
more strongly associated with ALD. The risk of CVD in NAFLD
increases in a dose dependent manner in line with the severity
of NAFLD (especially, fibrosis stage)9,10 and alcohol consump-
tion in ALD.11 Over 20 retrospective and prospective studies
have investigated the relationship between NAFLD and CVD,019 vol. 70 j 1203–1213
with the majority of NAFLD cases showing increased CVD mor-
bidity and mortality, independent of metabolic phenotypes.12
Furthermore, the relationship between liver disease and CVD,
extends to fibrosis stage. In comparison with a matched refer-
ence population, patients with NAFLD and fibrosis were more
likely to die from CVD and liver-related disease, specifically
those with stage 3 or 4 fibrosis.13
Although the relationship between liver disease and CVD is
well defined, the underpinning mechanisms are less well under-
stood. The presence of subclinical atherosclerosis has been
shown to be linked with disease severity in NAFLD.14 Further-
more, chronic low grade inflammation is a characteristic of
metabolic disorders, and may contribute to extrahepatic com-
plications.15 In particular, higher levels of circulating inflamma-
tory mediators associated with non-alcoholic steatohepatitis
(NASH) may also play a pathogenic role in CVD,16 activate sites
in the brain17 and increase sympathetic outflow.18 NASH and
fibrosis severity have also been linked with epicardial fat, mor-
phological and functional cardiac alterations and inflamma-
tion.19–23 Heavy alcohol consumption also increases the risk of
cardiomyopathy, hypertension, arrhythmias, stroke and cardiac
ischemia and altered autonomic function.11,24 Furthermore,
increased alcohol intake has shown to lead to weight gain and
obesity, further exacerbating the risk factors and overlap
between NAFLD and ALD.25
Changes in autonomic dysfunction predispose individuals to
cardiac arrhythmias, coronary artery disease and increased
mortality,26–33 all of which increase in patients with NAFLD
and ALD. Despite research supporting a link between NAFLD,
CVD, alcohol intake and autonomic dysfunction, to date studies
have not assessed both central haemodynamic and cardiac
autonomic measures simultaneously in individuals with NAFLD
and those with hepatic steatosis consuming >20 g/day of alco-
hol. Given that increased alcohol intake is linked to cardiac com-
plications, and CVD dictates clinical outcomes in patients with
NAFLD, a more detailed understanding of the potential mecha-
nisms leading to CVD in patients with >5% liver fat, in those con-
suming greater than and less than 20 g/day of alcohol, would
enable appropriate therapeutic interventions to be developed.
The primary aim of this study was to evaluate the relationship
between central haemodynamic and autonomic function in
combination with liver fat, while also assessing how any impair-
ment in cardiac and autonomic function is influenced by addi-
tional risk factors including alcohol, obesity, inflammation and
diabetes.
Patients and methods
A total of 96 sedentary patients (defined as <60 min of moderate
to vigorous activity per week) were recruited into the study. All
participants underwent assessment of liver fat, abdominal adi-
posity, autonomic function, body composition, blood biochem-
istry, and metabolic testing (Table 1). The cohort consisted of 3
groups: Group 1 – NAFLD: 46 patients with NAFLD, defined as
having a hepatic triglyceride content (HTGC) greater than 5%
by magnetic resonance spectroscopy (MRS), no other causes of
liver disease and consuming no alcohol or <20 g of alcohol per
day. This group included 27 patients who had histologically pro-
disease and consuming >20 g but <50 g of alcohol per day1,34
and Group 3 – CONTROL: 34 individuals who were non-
smokers, had no overt evidence of cardiac, liver or metabolic dis-
orders and who consumed no alcohol or <20 g of alcohol per day.
The studywas approved by Sunderland Research Ethics Commit-
tee, UK. All patients provided informed written consent and
were recruited from primary (GP surgeries in Newcastle upon
Tyne, UK) and secondary care (Freeman Hospital,
Newcastle upon Tyne, UK) and had previously taken
part in the following studies: UK (REC 13NE/0041 and 12/
NE/0411, ISRCTN90597099: http://www.isrctn.com/ISRCTN905
97099 and ISRCTN16070927: http://www.isrctn.com/ISRCTN16
070927).
Individuals with evidence of other liver disease (autoim-
mune hepatitis, viral hepatitis, drug-induced liver injury,
haemochromatosis, cholestatic liver disease or Wilson’s disease)
were excluded. Other exclusion criteria included: heart (alco-
holic cardiomyopathy or otherwise related) or kidney disease,
dietary change over the preceding 6 months and insulin sensi-
tising treatment (for patients with type 2 diabetes, only diet
and metformin-controlled individuals were accepted, and it
was a requirement that they were stable for at least 6 months
prior to assessment). Alcohol levels were assessed by a suitably
trained member of the research team as an average over the last
year and then confirmed by hepatologists (SM, SMc, CD and QA)
(Table 1).
Screening visit
During the screening visit a full medical history and physical
examination was completed. Individuals from Groups 1 and 2
then completed a progressive peak exercise test to screen for
any undiagnosed cardiac disease. Supine resting 12-lead elec-
trocardiogram (ECG) (Custo med GmbH, Ottobrunn, Germany)
and blood pressure measures (Suntech Tango+, Suntech Medical
Ltd, Oxford) were conducted. Patients were then seated on an
electronically braked recumbent cycle ergometer (Corival Lode
BV, Groningen, Netherlands) to assess cardiac function and
VO2 peak. Following a 5-min warm up at 25 W, resistance was
increased by 1 W per 8 seconds until volitional exhaustion
was reached or patients were unable to maintain a cadence of
60–70 rpm. The ECG was used to continuously monitor heart
function and blood pressure was measured every 2 min during
the exercise test. Expired gases were collected using a Hans
Rudolf breathing mask and analysed online for oxygen, carbon
dioxide and minute ventilation (CORTEX Biophysik, Leipzig,
Germany).
Anthropometry
For individuals from Group 1 and 2 body weight was measured
using an electronic scale and air displacement plethysmography
(BodPod, Life Measurement Inc., CA, USA).35 Height was mea-
sured with a stadiometer (SECA 799, SECA UK).
Liver steatosis and abdominal fat measurement
For individuals from Groups 1 and 2, magnetic resonance stud-
ies were performed using a 3.0 Tesla Philips Achieva scanner
(Philips Medical Systems, Best, The Netherlands). HTGC was
measured by localised T2-corrected 1H-magnetic resonance
Research Article Genetic and Metabolic Diseasesven NASH (liver histology and NAFLD fibrosis reported in
Table 1); Group 2 – DAFLD. Hepatic steatosis and alcohol drin-
kers (dual aetiology fatty liver disease [DAFLD]): 16 patients
with HTGC greater than 5% using MRS, no other causes of liver
1204 Journal of Hepatology 20spectroscopy (PRESS, TR/TEs = 3,000 ms/36, 50, 75, 100, 125,
150, voxel size 3  3  3 cm). Lipid volume fractions were cal-
culated according to previous research36 by integration of the
lipid resonances between 0.5–3.0 ppm and the water and lipid
19 vol. 70 j 1203–1213
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OF HEPATOLOGYresonances between 3.0–5.5 ppm, using the 3DiCSI software
(Columbia University, USA). Subcutaneous and visceral fat were
measured at the L4/L5 junction using a three-point Dixon
Table 1. Mean (SD) baseline characteristics.
Control (n = 34) N
Anthropometry
Age (years) 52 (9)
BMI (kg/m2) 27 (3)
Gender (M/F) 23/11
VO2PEAK (ml/kg/min) –
LT (ml/kg/min)
Peak exercise HR (b/min)
Resting RQ
Alcohol intake (g/wk)
Women –
Men –
Smoking status (%) 0
HTGC (%) –
Visceral fat (cm2) –
Subcutaneous fat (cm2) –
Metabolic
ALT (U/L) –
AST (U/L) –
GGT (U/L) –
Cholesterol (mmol/L) –
Triglyceride (mmol/L) –
F–Glucose (mmol/L) –
2 h fsOGTT (mmol/L) –
Insulin (pmol/L) –
HbA1c (%) –
HOMA–IR –
IL–6 –
TNFa –
CK–18 –
Type 2 diabetes (%) –
Metformin –
Sulfonylureas –
Thiazolidinediones –
GLP–1 Receptor Agonist –
DPP–4 Inhibitors –
Insulin –
Hypertension (%) –
ARB –
ACE–1 –
BB –
CCB –
Liver histology and NAFLD fibrosis
NAS –
Steatosis –
Inflammation –
Ballooning –
Fibrosis Stage –
0 –
1 –
2 –
3 –
4 –
Alcohol consumption presented as range. LT, lactate threshold; HR, heart rate; RQ,
alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltr
tolerance test; HbA1c, glycated haemoglobin; HOMA-IR, homeostasis model assessm
cytoketatin-18, BP, blood pressure. GLP-1, glucagon-like peptide-1; DPP-4, dipepti
enzyme; BB, beta blockers; CCB, calcium channel blockers; NAS, non-alcoholic fatty
centage of patients from total number of patients on medication. CK-18 (mean and SD
Wallis test and within group differences using a Wilcoxon signed-rank (2 way) tes
difference at p <0.05 and <0.01, respectively.Journal of Hepatology 20FLD (n = 46) DAFLD (n = 16) Between group p value
54 (13) 55 (10) 0.66
32 (5) 32 (5) 0.01*
28/18 12/4 0.55
22 (6) 22 (5) 0.87
15 (4) 14 (5) 0.53
152 (21) 153 (18) 0.70
0.9 (0.2) 0.9 (0.1) 0.45
– 140–168 –
– 231–273 –
4 13 0.30
13 (7) 13 (6) 0.99
202 (74) 173 (91) 0.25
351 (133) 341 (104) 0.78
64 (43) 52 (22) 0.27
46 (23) 44 (23) 0.74
102 (144) 110 (103) 0.96
4.8 (1.4) 5.6 (1.2) 0.06
1.9 (0.9) 1.9 (0.9) 0.76
6.1 (1.8) 5.5 (0.5) 0.23
9.3 (3.9) 8.5 (3.1) 0.45
19 (11) 18 (9) 0.80
47 (12) 39 (4) 0.01#
1.6 (1.1) 1.8 (0.9) 0.64
1.2 (0.6) 1.7 (1.1) 0.08
3.6 (1.8) 4.3 (1.6) 0.14
633 (876) 247 (153) 0.04#
48 56 0.07
42 25 –
13 1 –
8 – –sequence as previously described.37 All measurements for
HTGC, visceral and subcutaneous fat were blinded for all liver
patients only (i.e. Groups 1 and 2).
4 6 –
38 62 0.05
6 6 –
19 63 –
6 6 –
13 19 –
5 (2–7) – –
2 (1–3) – –
2 (1–3) – –
1 (1–2) – –
3 (0–3) – –
1 (4%) – –
2 (8%) – –
8 (33%) – –
13 (54%) – –
0 (0%) – –
spiratory quotient; HTGC, hepatic triglyceride content; BMI, body mass index; ALT,
sferase; F-Glucose, fasting glucose, 2 h fsOGTT, 2 h frequently sampled oral glucose
t-insulin resistance; TNF-a, tumour necrosis factor-alpha; IL-6, interleukin 6, CK-18,
l peptidase 4: ARB, Angiotensin II receptor blockers; ACE, angiotensin-converting
iver disease activity score; NASH, non-alcoholic steatohepatitis. Medication – per-
liver histology and fibrosis stage are median (range) for patients with NASH. Kruskal-
oth controlling for BMI. Values are means (SD). # and * denotes a between group19 vol. 70 j 1203–1213 1205
Liver histology
A subset of Group 1 patients (NAFLD, n = 27) had a histological
diagnosis of NASH. These biopsies were conducted as part of
their routine clinical care. The liver biopsies were scored by
expert hepatopathologists (ADB and DT) according to the NASH
Clinical Research Network criteria.38 NAFLD activity score (NAS)
ranges between 0–8, which included scoring for steatosis (0–3),
lobular inflammation (0–3) and hepatocyte ballooning (0–2)
and fibrosis is staged from 0 to 4. NASH was defined as steatosis
with hepatocyte ballooning degeneration, hepatic
inflammation ± fibrosis.
Cardiac haemodynamic and autonomic regulation
Patients were fasted overnight for a minimum of 8 h, instructed
to consume only water prior to their visit and to avoid exercise
for 24 h prior to this visit. All testing was performed at the same
time of the day to exclude any diurnal variation in parameters.
All cardiac haemodynamic and autonomic regulation data were
recorded using a Task Force Monitor (TFM, CNSystem, Medizin-
technik, Graz, Austria) where patients lay supine for 10 min
acclimatisation, followed by 20 min of recording, as previously
described.39 Briefly, heart rate was assessed by continuous
ECG, and beat-to-beat stroke volume, cardiac output and cardiac
output index (CI) were assessed using impedance cardiogra-
phy.40 Beat-to-beat blood pressure was measured by a vascular
unloading technique41 which was corrected automatically to
the oscillometric blood pressure measured on the contralateral
arm. Beat variables measured included heart rate, diastolic
blood pressure (DBP), systolic blood pressure (SBP) and mean
blood pressure (MBP). Cardiac variables were normalised for
total body surface area and included stroke volume index
(SVI), CI, total peripheral resistance index (TPRI), end diastolic
index (EDI), index of contractility (IC), acceleration index
(ACI), left ventricular ejection time (LVET), thoracic fluid content
(TFC), heather index (HI) and total arterial compliance (TAC).
Heart rate variability, blood pressure variability and barore-
ceptor variability were all assessed using power spectral analy-
activator polymer gel containing vacutainers (BD Diagnostics,
Plymouth, UK). Total cholesterol, triglycerides, ALT, AST, and
GGT were measured using a Roche Modular P and test kits
(Roche Diagnostics Ltd, Burgess Hill, UK). HbA1c was measured
using a TOSOH HLC-723G7 (Tosoh Corporation, Tokyo, Japan).
Cytokines (tumour necrosis factor-alpha (TNF-a) and inter-
leukin 6 (IL-6)) were measured V-PLEX plate (K15049D plate,
Meso-Scale) and non-invasive scores for disease activity mea-
sured cell death (fragments of CK-18 using M30-Apoptosense
ELISA kit, PEVIVA, Bromma, Sweden).
Statistics
Between group differences were assessed using a Kruskal-
Wallis test and within group differences using a Wilcoxon
signed-rank (2-way) test both controlling for body mass index
(BMI). Bivariate correlations using Spearman rank correlations
were conducted to investigate any associations between base-
line characteristics, resting central haemodynamic and cardiac
autonomic measures for liver patients only. Multiple linear
regression models were used to investigate the associations
between HTGC, fibrosis score, CK-18 and TNF-a and cardiac
variables (CI, SVI and EDI) and autonomic variables (barorecep-
tor sensitivity, LFnu-DBP and SBP and HF-DBP and SBP). Models
were fit to estimate associations after the adjustment of age,
gender, BMI, diagnosis of type 2 diabetes, smoking status and
HbA1c. Statistical significance was set at p <0.05. Statistical anal-
yses were performed using SPSS statistical analysis software
(Version 19, IBM, predictive Analysis Software, USA). All authors
had access to the study data and reviewed and approved the
final manuscript.
Results
Baseline characteristics of participants are presented (Table 1).
The mean age and gender distribution were similar across the
3 groups. The 2 groups of patients with hepatic steatosis had
a significantly higher BMI (p <0.01) when compared to the con-
Research Article Genetic and Metabolic Diseasessis, which has demonstrated to be a simple and non-invasive
method for analysing autonomic mechanisms.42 Briefly, heart
rate interval variability was calculated by comparing low fre-
quency (LF – predominantly sympathetic activity) (0.05–
0.17 Hz) with high frequency (HF – parasympathetic activity)
(0.17–0.40 Hz) whilst correcting for the R-R interval of the
ECG complex. Using power spectral analysis and applying an
autoregressive methodology, SBP and DBP variability (0.05–
0.17 Hz) were measured using absolute and normalised val-
ues.41 LF/HF ratio for heart rate and blood pressure variability
were measured as the ratio between LF (sympathetic activity)
and HF (parasympathetic activity). Baroreceptor variability
was measured using the sequence technique43 and baroreceptor
effectiveness index was calculated as the ratio of baroreceptor
sequences (or events) as related to the number of blood pres-
sure ramps.
Fasting biochemistry
Fasting samples were analysed for Groups 1 and 2 in a Clinical
Pathology Accredited laboratory (Newcastle Upon Tyne Hospital
NHS Foundation Trust, Department of Clinical Biochemistry). Glu-
cose, insulin, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), gamma-glutamyltransferase (GGT), total
cholesterol, triglycerides and glycated haemoglobin (HbA1c)
were measured. Plasma samples were collected in silica clot1206 Journal of Hepatology 20trol group. The patients with NAFLD had similar baseline char-
acteristics to the DAFLD group. HbA1c and CK-18 levels were
significantly higher in the NAFLD group (p <0.05).
Comparison of resting central haemodynamic and autonomic
measures between individuals with hepatic steatosis (Groups
1 and 2) and controls
Table 2 presents a comparison of the central haemodynamics
and cardiac autonomic measures between individuals with
NAFLD, DAFLD and controls. Beat variables including heart rate,
blood pressure (Fig. 1) and SVI were significantly different
between the controls and patients with >5% HTGC (p <0.01).
Cardiac variables (EDI, IC, ACI, LVET, TFC, HI and TAC) were all
significantly lower in the patients with hepatic steatosis com-
pared to controls (p <0.01), indicating that the hearts of individ-
uals with >5% HTGC were less efficient in filling and contracting
than those of the controls.
There were significant differences in heart rate variability
and DBP and SBP variability between the control group and
those with hepatic steatosis (p <0.05). LFnu-RRI (sympathetic
activity), LF/HF-RRI (sympathetic activity/parasympathetic
activity ratio) for heart rate were both lower and HFnu-RRI
(parasympathetic activity) variability was higher in the control
group (p <0.01) when compared to individuals with hepatic
steatosis. HFnu-DBP and HFnu-SBP were higher and LF/HF-dBP19 vol. 70 j 1203–1213
and LF/HF-sBP were significantly lower in those with hepatic
steatosis when compared with the controls (p ≤0.01, Table 2,
Fig. 1). CI, baroreceptor sensitivity, total peripheral resistance,
Table 2. Mean (SD) resting central haemodynamic and cardiac autonomic m
Control (n = 34) NAF
Beat
HR (n/1) 63 (9)
SBP (mmHg) 119 (9)
DBP (mmHg) 79 (7)
MBP (mmHg) 94 (8)
SV (ml) 81 (26)
SI (ml/m2) 42 (12)
CO (L/min) 5.0 (1.6)
CI (L/min/m2) 2.6 (0.77)
TPRI (dyn*s*m2/cm5) 3,007 (854) 3
Cardiac
EDI (ml/m2) 68 (18)
IC (1,000/s) 44 (18)
ACI (100/s2) 58 (23)
LVET (ms) 322 (15)
TFC (1/Ohm) 29 (5)
HI (1/s2) 0.20 (0.11)
TAC (ml/mmHg) 2.0 (0.7)
Heart rate variability
LFnu-RRI (%) 61 (14) 51 (16) 54 (20) 0.01*
HFnu-RRI (%) 38 (14) 49 (16) 46 (20) 0.01*
LF/HF-RRI (n/1) 2.2 (1.4)
Diastolic blood pressure variability
LFnu-DBP (%) 45 (13)
HFnu-DBP (%) 11 (5)
LF/HF-DBP (n/1) 4.8 (2.7)
Systolic blood pressure variability
LFnu-SBP (%) 44 (13)
HFnu-SBP (%) 14 (6)
LF/HF-SBP (n/1) 3.4 (1.5)
Baroreceptors reflex sensitivity
Total-events event count (n/1) 46 (37)
HR, heart rate, SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean
cardiac output index; TPRI, total peripheral resistance index; EDI, end diastolic index; I
TFC, thoracic fluid content; HI, heather index: TAC, total arterial compliance; HRV, hea
frequency; BRS, baroreceptor sensitivity; DAFLD, dual aetiology fatty liver disease; NAFL
using a Wilcoxon signed-rank (2-way) test both controlling for BMI. Values are means
¥denotes a significant difference between NAFLD and DAFLD group at p ≤0.05. Full com
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OF HEPATOLOGYLFnu-DBP (sympathetic activity) and LFnu-sBP (sympathetic
activity) were not significantly different between the groups
(p >0.05). Overall, these findings indicate that individuals with
hepatic steatosis have a greater degree of autonomic dysfunc-
tion compared to controls.
Comparison of resting central haemodynamic and cardiac
autonomic measures between patients with NAFLD and
DAFLD
The baseline demographic and clinical characteristics were very
similar in the NAFLD and DAFLD groups (Table 1). However,
MBP was 5% higher in the DAFLD group (p ≤0.02). Moreover,
the parasympathetic activity was 29% lower (% HFnu-DBP)
and 26% higher (LF/HF-DBP ratio) in the DAFLD group than
those with NAFLD (p = 0.03 and 0.04, respectively, Table S1).
Relationship between cardiac and metabolic indices for
patients with hepatic steatosis (NAFLD and DAFLD combined)
There was a significant positive association between HTGC and
baroreceptors reflex sensitivity (r = 0.27, p = 0.04) and a nega-
tive association between HTGC and SVI (r = 0.30, p = 0.02)
(Fig. 2) and EDI (r = 0.28, p = 0.03). HTGC was also negativelyJournal of Hepatology 20easures for controls and patients with hepatic steatosis.
LD (n = 46) DAFLD (n = 16) Between group p value
68 (9) 70 (9) 0.01#
127 (15) 131 (11) 0.01#
84 (10) 85 (10) 0.01#
99 (12) 104 (9) ¥ 0.01#
74 (18) 68 (15) 0.09
35 (9) 35 (9) 0.01#
4.9 (1.1) 4.6 (0.5) 0.60
2.4 (0.5) 2.4 (0.6) 0.50
,449 (959) 3,603 (1,044) 0.08
57 (18) 53 (13) 0.01#
33 (12) 32 (13) 0.01#
42 (19) 44 (19) 0.01*
309 (20) 308 (18) 0.01*
24 (5) 26 (6) 0.01*
0.19 (0.10) 0.18 (0.10) 0.01#
1.7 (0.5) 1.6 (0.4) 0.02associated with CI (r = 0.28, p = 0.03) (Fig. 2), left ventricular
work index (r = 0.30, p = 0.02), IC (r = 0.29, p = 0.03) and HI
(r = 0.28, p = 0.03). Furthermore, there was a significant nega-
tive correlation between HTGC and VO2peak (r = 0.47, p = 0.01),
peak heart rate (r = 0.23, p = 0.08) and lactate threshold
(r = 0.27, p = 0.04) (Fig. 3). The associations between HTGC,
cardiac, autonomic and exercise variables suggest that greater
HTGC may be associated with reduced cardiac function. BMI
was significantly negatively associated with all cardiac variables
(p ≤0.05), beat variables (SVI and CI) (p ≥ 0.05) and autonomic
variables (LFnu-RRI (%), LFnu-DBP and LFnu-SBP) (p = 0.05).
There were also significant positive associations between BMI
and beat variables (heart rate, SBP, DBP, MBP and TPRI)
(p ≤0.05) and autonomic variables HFnu-RRI (%), HFnu-DBP
and HFnu-SBP (p = 0.05). Subcutaneous fat (SAT) was also signif-
icantly positively correlated with TPRI (r = 0.30, p = 0.01),
LFnu-DBP (r = 0.30, p = 0.02), LF/HF-DBP (r = 0.23, p = 0.04) and
LF/HF-SBP (r = 0.22, p = 0.05), suggesting that body mass and
body composition have a significant impact upon cardiac and
autonomic function. There was also a significant negative asso-
ciation between fasting glucose and CI (r = 0.27, p = 0.04)
(Fig. 2) and EDI (r = 0.27, p = 0.03). Cholesterol was negatively
correlated with stroke volume (r = 0.27, p = 0.03), SVI
(r = 0.27, p = 0.04) and TPRI (r = 0.27, p = 0.04). There was
also a trend towards a negative association between triglyceride
1.5 (1.0) 1.6 (1.4) 0.03#
43 (11) 48 (14) 0.61
24 (12) 17 (10)¥ 0.01*
3.0 (2.0) 3.8 (2.2)¥ 0.01*
39 (11) 42 (13) 0.20
26 (14) 24 (14) 0.01*
2.3 (1.7) 2.3 (1.5) 0.01*
76 (69) 55 (34) 0.20
blood pressure; SV, stroke volume; SVI, stroke volume index; CO, cardiac output; CI,
C, index of contractility; ACI, acceleration index; LVET, left ventricular ejection time;
rt rate variability; LF, low frequency; nu, normal units; RRI, R to R interval; HF, high
D, non-alcoholic fatty liver disease. Kruskal-Wallis test and within group differences
(±SD). # and * denote a between group difference of p ≤0.05 and <0.01, respectively.
parison between NAFLD and DAFLD group table is presented in Table S1.19 vol. 70 j 1203–1213 1207
levels and stroke volume (r = 0.28, p = 0.08). Homeostasis
model assessment-insulin resistance (HOMA-IR) was positively
correlated with LF heart rate variability (r = 0.27, p = 0.03) and
negatively correlated with HF heart rate variability (r = 0.27,
p = 0.03). HbA1c was significantly negatively associated with
heart rate (r = 0.30, p = 0.01) (Fig. 2). There was a significant
negative association between fasting glucose and SBP
(r = 0.26, p = 0.04), SV (r = 0.26, p = 0.04) and CO (r = 0.31,
p = 0.02) and a significant positive correlation between LF-nu
DBP (r = 0.30, p = 0.02), SBP (r = 0.44, p <0.01), baroreceptor sen-
sitivity (r = 0.33, p = 0.01) and TNF-a. Collectively, these findings
suggest insulin resistance, dyslipidaemia and inflammation are
associated with reduced cardiac and autonomic function in
these individuals with hepatic steatosis.
Relationship between cardiac and metabolic indices for
patients with histologically diagnosed NASH
In the 27 patients with NASH, fibrosis stage was significantly
These findings suggest that there is an association between
advanced liver fibrosis and reduced cardiac and autonomic
function in these individuals with NASH.
Multiple linear regressions
The data presented in Table 3 generated from the multiple lin-
ear regressions show the associations of TNF-a, CK-18, HTGC
and fibrosis scoring with cardiac and autonomic variables. There
were strong inverse associations with cardiac variables CI, SVI
and EDI and HTGC when controlling for age, gender, BMI, diag-
nosis of type 2 diabetes, HbA1c and smoking. There were signif-
icant associations between TNF-a and autonomic variables
(baroreceptor sensitivity, LFnu-DBP and SBP). CK-18 was also
significantly associated with HFnu-DBP and SBP. These findings
demonstrate that liver fat is independently associated with car-
diac function, but not autonomic function. However, inflamma-
tion (TNF-a and CK-18) was independently associated with
autonomic dysfunction but not cardiac function.
Discussion
This is the first study to explore cardiac and autonomic function
in combination in a well characterised cohort of individuals
with hepatic steatosis associated with NAFLD and alcohol
intake. The main findings of this study were that patients with
>5% HTGC had evidence of impaired cardiac and autonomic
function when compared with controls. These differences
appeared to be dependent on the degree of HTGC and metabolic
dysfunction, inflammation and to a lesser extent the presence of
increased alcohol consumption. Additional sub-analyses indi-
cated that fibrosis staging may also be a key contributor
towards the degree of cardiac and autonomic dysfunction, con-
firming previously published data.13 These findings are of clini-
cal importance as patients with NAFLD, especially those with
advanced fibrosis have an increased risk of cardiac death. Defin-
ing the pathophysiology of cardiac and autonomic dysfunction
in patients could help identify therapeutic interventions to
reduce cardiac risk.
Using sensitive measures in a well-defined group, we have
been able to demonstrate that liver disease is associated with
impaired cardiac function, including reductions in CI and pump-
ing capability, and increases in blood pressure and total periph-
eral resistance. It is important to acknowledge that body surface
area indexed cardiac variables reported here, may not be as clin-
ically accurate in obese liver patients as imaging techniques that
account for left ventricular mass and height.44 To account for
this we controlled for BMI, and in addition to CI, we reported
significant differences in additional cardiac variables, all of
which contribute to cardiac function and pumping capability.
These observations are supported by previous studies con-
ducted by our group where MRI imaging techniques have been
used.19,45 These have shown that the hearts of patients with
chronic liver disease, regardless of the aetiology, do not function
as well as those of controls.19,46–48 The cause of the underlying
cardiac dysfunction associated with NAFLD is not known. Here
we demonstrate that liver fat and fasting glucose were nega-
tively correlated with cardiac output variables.
Previous reports have demonstrated that liver fat predicts
the presence of impaired myocardial metabolism and cardiac
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Research Article Genetic and Metabolic Diseasesnegatively associated with DBP (r = 0.47, p = 0.02), MBP
(r = 0.47, p = 0.02), HFnu-dBP (r = 0.55, p ≤0.01), LF/HF-dBP
(r = 0.58, p ≤0.01) and HFnu-sBP (r = 0.42, p = 0.04).1208 Journal of Hepatology 20dysfunction.49,50 Multiple linear regression analyses conducted
for the present study have supported this by showing that liver
fat was independently associated with cardiac function when19 vol. 70 j 1203–1213
controlling for type 2 diabetes diagnosis, HbA1c, age, gender and
BMI (Table 3). Hyperglycaemia, elevated levels of circulating
triglycerides and cholesterol (surrogate biomarkers for non-
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1210 Journal of Hepatology 20uptake of triglycerides and NEFA in cardiomyocytes prevents
downstream insulin pathways, inducing cardiac insulin resis-
tance.54 Triglycerides and NEFA are then preferentially utilised
by the heart over glucose, subsequently reducing cardiac con-
tractile efficiency (reducing phosphocreatine/adenosine
triphosphate ratio).50 The findings presented here support this
close relationship between metabolic and cardiac dysfunction,
where liver fat, fasting glucose, triglycerides and cholesterol
all negatively impact upon various cardiac variables. Under-
standing the pathophysiology of cardiac changes associated
with hyperglycaemia and elevated lipids in patients is crucial
to identifying potential therapeutic interventions that reduce
the risk of CVD and liver disease.
The data presented extend beyond cardiac function to reveal
significant changes in autonomic function recognised as a pow-
erful predictor of morbidity and mortality in NAFLD.30,55 This is
unsurprising given the role of the sympathetic and parasympa-
thetic systems, which are responsible for controlling cardiac
function through information provided by the baroreceptors.56
Our findings reveal increased baroreceptor sensitivity, both sys-
tolic and diastolic parasympathetic activity in patients with
NAFLD, and impaired cardiac function. In contrast, Ziegler,
et al.31 reported that reduced parasympathetic activity was
strongly associated with liver fat in newly diagnosed type 2 dia-
betes, but did not confirm any impairments in cardiac function.
These differences may have been due to disease duration – i.e.
the patients in the current study had a diagnosis of >5% hepatic
steatosis of >3 years. Frith, et al.,57 suggested that disease dura-
tion, alongside disease status may have a direct impact upon the
degree of autonomic dysfunction. In patients with a confirmed
diagnosis of >5% hepatic steatosis, among other metabolic risk
factors shown here, increased parasympathetic activity may
be a compensatory mechanism to maintain cardiac function,
but eventually becomes part of the disease. Patients with >5%
hepatic steatosis may therefore be suffering from pathological
sympathetic activity,57 leading to autonomic effects, such as
heart and blood vessels becoming resistant to parasympathetic
activity. Impaired response of the cardiovascular system to
parasympathetic activity places additional stress on the cardio-
vascular system, evident here by increased heart rate, blood
pressure, and impaired cardiac contractibility and output and
attenuated heart rate variability, as previously reported in
NAFLD and diabetes.31,55
Sustained sympathetic activity has been shown to be a stim-
ulus for structural and functional changes in cardiomyocytes
and interstitium, left ventricular re-modelling,58 ventricular
tachyarrhythmia and sudden cardiac death.59 Although the pre-
cise mechanism linking autonomic dysfunction and chronic
liver disease remains unclear, insulin resistance and inflamma-
tion have received interest for their potential contributions.
Insulin resistance has been shown to increase circulating insu-
lin, glucose and renal spill-over of noradrenaline.60 Supporting
the links with insulin resistance56,60,61 the present data showed
that HOMA-IR, a measure of insulin resistance, was significantly
associated with heart rate variability, indicating increased sym-
pathetic and decreased parasympathetic activity. Elevated
levels of insulin (via glucose metabolism in the ventral medial
hypothalamus) and noradrenaline increase sympathetic stimu-
lation,56 induce myocardial injury, impair b-adrenergic func-
tion62 and damage nerve endings,63 all of which could
contribute to autonomic disturbance in individuals with exces-
sive liver fat. Although the precise mechanism of autonomic19 vol. 70 j 1203–1213
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OF HEPATOLOGYfunction remains unknown, earlier detection of those at risk
would allow hepatologists to co-ordinate with cardiologists to
aggressively treat these patients with lifestyle interventions
and/or pharmaceutical treatments.
Interestingly, increased alcohol consumption was associated
with lower parasympathetic activity and increased blood pres-
sure and sympathetic activity. The increase in blood pressure
observed here appears to be driven by alterations in autonomic
function during diastole (Fig. 1). Excessive alcohol is well estab-
lished for its role in progressive liver disease64 and increased
risk of cardiovascular disease.65 Elevated blood pressure is com-
monly reported when consuming excessive levels of alcohol,66
although precise mechanisms are unknown. Amongst potential
mechanisms, pre-clinical data have demonstrated that
increased ethanol consumption was associated with increased
sympathetic activity, SBP and attenuated baroreceptor sensitiv-
ity.67 Therefore, patients consuming >20 g of alcohol per day
and who have >5% liver fat may be exposed to a dual aetiology,
and an increased risk of CVD,11,24 when compared with NAFLD
patients. Although patients with NAFLD are advised to drink
<20 g of alcohol per day, recent reports have demonstrated that
more patients are being recognised in the clinical setting who
are obese with fatty liver, but are consuming >30 g/day of alco-
hol, and in some patients metabolic syndrome was more fre-
quent in those consuming >30 g/day of alcohol.68,69 The
potential risk of consuming excessive amounts of alcohol, com-
bined with metabolic dysfunction may further accentuate the
clinical and economic burden of CVD and liver disease.In addition to metabolic dysfunction, obesity and inflamma-
tion, have also been identified as potential contributing factors
towards the progression of autonomic dysfunction.18,70 In the
current study, BMI and subcutaneous fat were associated with
impaired cardiac and autonomic function, supporting previous
observations.71 Furthermore, elevated inflammation is com-
15monly reported in obese and overweight individuals. In the
current study we were able to demonstrate that TNF-a was
independently associated with sympathetic (low frequency)
activity (DBP and SBP) and baroreceptor sensitivity, although
it is difficult to ascertain whether TNF-a is specifically liver
related or due to patients’ body composition. However, we have
also shown that CK-18, a blood indicator of hepatocellular
injury was independently associated with parasympathetic
activity (high frequency) for both DBP and SBP, further suggest-
ing that increased parasympathetic activity may initially be a
compensatory mechanism to maintain cardiac function in
patients with excessive liver fat.57 Furthermore, in a sub-
analysis of patients with NASH, fibrosis staging was negatively
correlated with cardiac and autonomic function, although this
could not be confirmed in the multivariate linear regression
analyses, likely due to the small sample size.
Combined, these data suggest that inflammation (TNF-a and
CK-18) and NASH severity may have a direct impact upon car-
diac and autonomic dysfunction, placing these patients at a
greater risk of cardiac arrhythmias and increased mortality. This
premise is supported by previous data linking severity of liver
histopathology with atherogenesis, cardiomyopathy and
arrhythmias48,72 and increased mortality.9 NASH is charac-
terised by liver fat, liver inflammation and metabolic syndrome,
all of which are associated with inflammation through various
mechanisms.73 Inflammation has also been identified in auto-
nomic dysfunction, through its ability to activate a number of
17sites in the brain, interacting with autonomic control and
Journal of Hepatology 20increasing sympathetic outflow,18,70 and in doing so increasing
the stress placed on the cardiovascular system. However, data
linking inflammation and autonomic dysfunction in clinical
practice is lacking.
Increased stress on the heart through altered sympathetic
activity and a defective parasympathetic response could con-
tribute to functional and structural cardiac changes. Hallsworth,
et al.19 and Cassidy, et al.45 have previously reported cardiac
structure and functional changes in similar cohorts of patients
with NAFLD and type 2 diabetes mellitus in the presence of ele-
vated liver fat and HOMA-IR. The present data, alongside these
studies, further substantiate the suggestion that the degree of
HTGC and metabolic dysfunction lead to autonomic dysfunction
and cardiac impairments. Autonomic dysfunction has been pre-
viously reported in chronic liver diseases,74 however, the link
between alcohol, disease severity and the degree of autonomic
dysfunction is equivocal due to conflicting results.75–77 A poten-
tial explanation for the difference in observations may in part be
the consequence of variations in methods and patient selection.
The present study addresses this with the use of standardised
methods and a well characterised patient cohort. In doing so
the present autonomic data support the need to identify and
treat patients with >5% HTGC, and those who continue to drink
>20 g of alcohol per day and who have >5% HTGC as they may
appear to have greater levels of autonomic dysfunction, placing
them at a greater risk of CVD. Although longitudinal studies are
required to assess the aetiology and time course of cardiac and
autonomic changes associated with increased HTGC and meta-
bolic dysfunction. One potential hypothesis may be that there
is a 2-hit effect, with the first hit being hyperglycaemia and ele-
vated circulating lipids inducing loss of contractile efficiency
and cardiac hypertrophy, and the second, subsequent hit an
impairment of the autonomic control due to cardiovascular re-
modelling. Alternatively, autonomic control may initially be
impaired, followed by cardiac structural and functional changes.
The direction of causality between impaired cardiac and auto-
nomic function remains unknown, and prospective and longitu-
dinal studies are warranted.
The present study is not without limitation. Although the
control group was matched for age and gender, BMI was lower
than that of the hepatic steatosis groups. However, this was
controlled for in the statistical analyses and accounted for when
reporting beat and cardiac variables. Cardiac haemodynamic
and autonomic variables were assessed using impedance car-
diography, which is not the recognised gold standard. However,
thermodilution methods were not considered appropriate due
to ethical issues, i.e. it would have been ethically difficult to
expose liver patients to this invasive procedure. There was no
assessment of liver fat in the control group. MRS was used to
determine HTGC; although it would have been beneficial to
assess liver histology for all hepatic steatosis patients as it is
likely that some may have had NASH and hepatic fibrosis, how-
ever, this was ethically difficult to justify exposing low risk
patients to a liver biopsy. Medication is likely to have affected
cardiac and autonomic functions, although, the levels across
groups were similar in patients with hepatic steatosis. The data
in the present study are observational in nature; it would have
been beneficial to conduct longitudinal studies to assess causal-
ity of whether autonomic function leads to cardiac changes,
whether cardiac changes lead to autonomic dysfunction, or
whether they occur concurrently. However, this study repre-
sents an important first step.
19 vol. 70 j 1203–1213 1211
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There is strong evidence linking liver disease and CVD, however,
evidence linking autonomic dysfunction and liver disease in the
pathology of CVD is lacking. Here we have shown that patients
with hepatic steatosis greater than 5% had significant impair-
ments in cardiac and autonomic function. These impairments
appeared to be dependent on HTGC, metabolic dysfunction,
inflammation and fibrosis staging. Alcohol intake enhanced
the impact of liver fat on diastolic autonomic control. Combined,
these data highlight cardiac and autonomic dysfunction as
potential therapeutic targets in patients with hepatic steatosis.
It is also important to understand the interaction between
metabolic dysfunction, alcohol and liver fat on the development
and progression of liver and cardiovascular disease. Clinical care
teams should explore therapies to address these as a means to
mitigate the excess CVD risk.
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